Thomas P Bleck1. 1. The University of Virginia, Charlottesville, Virginia 22908-0394, USA. tblcek@virginia.edu
Abstract
PURPOSE OF REVIEW: Although conventional anticonvulsant agents can terminate status epilepticus in most cases, a substantial minority of patients develops medically refractory status and requires more aggressive care. This review explores the options available. RECENT FINDINGS: Increasing numbers of previously unexpected etiologies for refractory status epilepticus continue to be reported. There are also some promising new therapies on the horizon, both for the short and the longer terms. SUMMARY: Refractory status epilepticus, while a challenge to the intensivist, can be treated with drugs that are commonly used by intensivists. The cooperation of an interested electroencephalographer is vital.
PURPOSE OF REVIEW: Although conventional anticonvulsant agents can terminate status epilepticus in most cases, a substantial minority of patients develops medically refractory status and requires more aggressive care. This review explores the options available. RECENT FINDINGS: Increasing numbers of previously unexpected etiologies for refractory status epilepticus continue to be reported. There are also some promising new therapies on the horizon, both for the short and the longer terms. SUMMARY: Refractory status epilepticus, while a challenge to the intensivist, can be treated with drugs that are commonly used by intensivists. The cooperation of an interested electroencephalographer is vital.
Authors: Andrea O Rossetti; Tracey A Milligan; Serge Vulliémoz; Costas Michaelides; Manuel Bertschi; Jong Woo Lee Journal: Neurocrit Care Date: 2011-02 Impact factor: 3.210
Authors: Andres Fernandez; Hector Lantigua; Christine Lesch; Belinda Shao; Brandon Foreman; J Michael Schmidt; Lawrence J Hirsch; Stephan A Mayer; Jan Claassen Journal: Neurology Date: 2013-12-20 Impact factor: 9.910
Authors: Raoul Sutter; Gian Marco De Marchis; Saskia Semmlack; Peter Fuhr; Stephan Rüegg; Stephan Marsch; Wendy C Ziai; Peter W Kaplan Journal: CNS Drugs Date: 2017-01 Impact factor: 5.749
Authors: James J Riviello; Jan Claassen; Suzette M LaRoche; Michael R Sperling; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Lori Shutter; David M Treiman; Paul M Vespa; Rodney Bell; Gretchen M Brophy Journal: Neurocrit Care Date: 2013-04 Impact factor: 3.210
Authors: Laxmikant S Deshpande; Robert E Blair; Nisha Nagarkatti; Sompong Sombati; Billy R Martin; Robert J DeLorenzo Journal: Exp Neurol Date: 2007-01-09 Impact factor: 5.330